Tech Company Financing Transactions
KSQ Therapeutics Funding Round
KSQ Therapeutics secured a $80 million Series C funding round on 9/29/2018. Investors included Alexandria Venture Investments, Arch Venture Partners and Baillie Gifford.
Transaction Overview
Company Name
Announced On
9/29/2018
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series C
Investors
Proceeds Purpose
With the financing, KSQ will advance its first drug program into the clinic within the next 18 months and up to three additional oncology drug programs into IND-enabling studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
610 Main St. North 4th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Meeker
Chief Financial Officer
Douglas Pagán
Chief Financial Officer
John Trzupek
Chief Scientific Officer
Frank Stegmeier
Vice President
Caroline Dugopolski
Browse more venture capital transactions:
Prev: 9/29/2018: NetraDyne venture capital transaction
Next: 9/29/2018: SnapMD venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs